In August 2022, the U.S. Food and Drug Administration finalized a rule creating a new category of over-the-counter hearing aids that could be sold without a prescription, professional evaluation, or audiologist involvement. The stated goal of the regulation was to improve access to hearing care for the estimated 30 million Americans with hearing loss who were not seeking or obtaining treatment. But the OTC category has also generated significant confusion among consumers about what these products do, who they are appropriate for, and what they cannot replace.

What the OTC Category Was Designed For

The FDA's OTC hearing aid rule specifically targets adults 18 years and older with perceived mild to moderate hearing loss. The regulatory framework explicitly excludes children, adults with severe or profound hearing loss, and anyone with certain medical conditions — sudden hearing loss, asymmetric hearing loss, active ear pain, drainage, or tinnitus of recent onset.

The key phrase is "perceived mild to moderate hearing loss." The regulation is based on the consumer's self-assessment of their hearing, not on an audiometric evaluation. Multiple studies have shown that adults systematically underestimate the degree of their hearing loss, particularly in the early and moderate stages when the gradual nature of the decline makes the change difficult to perceive introspectively.

The Clinical Case for Professional Evaluation First

The audiological evaluation that precedes a prescription hearing aid fitting is not a formality — it is a diagnostic process with real clinical implications. Approximately 5 to 10 percent of adults who present for audiological evaluation have medically significant pathology identified during the assessment: asymmetric sensorineural hearing loss that warrants imaging to rule out vestibular schwannoma, unilateral conductive loss suggesting otosclerosis, sudden sensorineural hearing loss requiring urgent medical management, or aural fullness with low-frequency threshold change consistent with endolymphatic hydrops.

Beyond the identification of medical pathology, the audiometric evaluation establishes the specific configuration and degree of loss that determines what amplification prescription is appropriate. An OTC hearing aid, by definition, cannot be programmed to an individual audiogram — it relies on generic amplification curves or simplified self-fitting adjustments.

What OTC Products Can and Cannot Do

OTC hearing aids vary considerably in their technology, quality, and sophistication. Some, such as products from Sony and Jabra, represent genuine hearing health technology developed by established manufacturers and offer reasonable performance for mild, high-frequency loss in quiet conditions. Others are amplifiers with limited sound processing and poor noise management.

A pair of OTC hearing aids typically costs between $200 and $1,600 — substantially less than prescription hearing aids, which range from approximately $1,500 to $7,000 per pair at current market rates. For a person with documented mild hearing loss who has already undergone audiological evaluation, an OTC product may be a reasonable choice.

Real-Ear Measurement and Why It Matters

One of the most significant clinical differences between prescription and OTC hearing aid fittings is real-ear measurement verification. In a professional fitting, the audiologist places a thin probe microphone in the ear canal to confirm that the device is delivering the prescribed acoustic gain at each frequency. Without measurement, the fitting is based on the manufacturer's generic prediction, which research shows matches the real-ear target only about a third of the time.

The audiological profession's position is not that OTC hearing aids have no value — it is that they are not a substitute for evaluation, and that the decision about which path is appropriate should be an informed one. The evaluation is the investment; the device is the implementation.

References

  • FDA. (2022). Over-the-Counter Hearing Aids: Regulations for Affordability and Accessibility. FDA Final Rule.
  • Nieman, C.L., & Lin, F.R. (2023). "Expanding access to hearing health care for adults with hearing loss." JAMA Otolaryngology. 149(2):89–90.